<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16981">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885818</url>
  </required_header>
  <id_info>
    <org_study_id>ABATACEPT AND B CELL</org_study_id>
    <nct_id>NCT02885818</nct_id>
  </id_info>
  <brief_title>Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis</brief_title>
  <acronym>ABATACEPT_B</acronym>
  <official_title>Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abatacept disrupts T-cell coactivation signals in rheumatoid arthritis (RA). Its potential
      effects on B cells are not well described. This study will assess the effects of abatacept
      therapy on the phenotype and function of peripheral blood B cells in patients with RA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral blood B-cell phenotype changes</measure>
    <time_frame>3 months</time_frame>
    <description>Measure of the proportion of the main B-cell subsets (transitional, na√Øve, memory, plasmablasts) by FACS analysis before abatacept initiation and 3 months later.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In vitro B-cell function and regulatory properties</measure>
    <time_frame>3 months</time_frame>
    <description>In vitro culture of B cells from the patients to assess B cell inhibition of T cell proliferation before abatacept initiation and 3 months later.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with RA fulfilling ACR/EULAR criteria, in whom abatacept is started as part of
        their usual clinical care
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RA as defined by ACR/EULAR criteria

          -  Clinical indication to start abatacept therapy

        Exclusion Criteria:

          -  Treatment by rituximab in the previous year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques-Olivier Pers</last_name>
    <role>Study Director</role>
    <affiliation>CHRU de Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques-Olivier Pers</last_name>
    <email>pers@univ-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Divi Cornec</last_name>
    <email>divi.cornec@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PERS Jacques-Olivier</last_name>
    </contact>
    <investigator>
      <last_name>Divi Cornec</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>August 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
